Aflibercept for Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in Germany

2018 ◽  
Vol 2 (6) ◽  
pp. 539-549 ◽  
Author(s):  
Carsten Framme ◽  
Nicole Eter ◽  
Thomas Hamacher ◽  
Zoran Hasanbasic ◽  
Claudia Jochmann ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Macular Degeneration ◽  
Routine Clinical Practice ◽  
Age Related Macular Degeneration ◽  
Age Related

scholarly journals Preferential Hyperacuity Home Testing for Monitoring Intermediate Age-related Macular Degeneration in Routine Clinical Practice

2020 ◽  
Vol 3 ◽  
pp. 9
Author(s):  
Yue Zhao ◽  
Grant Hom ◽  
Thais Conti ◽  
Sumit Sharma ◽  
Alex Yuan ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Macular Degeneration ◽  
Care Center ◽  
Tertiary Care ◽  
Home Monitoring ◽  
Office Visit ◽  
Routine Clinical Practice ◽  
Age Related Macular Degeneration ◽  
Exudative Amd ◽  
Age Related

Objectives: A home monitoring device (ForeseeHome; Notal Vision, Tel Aviv, Israel) detected choroidal neovascularization in age-related macular degeneration (AMD) earlier than home and office monitoring. This study describes device usage in routine clinical practice. Materials and Methods: An Institutional Review Board-approved retrospective chart review of intermediate AMD patients who used the device at a single tertiary care center. Primary outcomes were duration and frequency of usage and outcomes of alerts generated. Results: Sixty-two patients (106 eyes) completed monitoring 4.2 ± 2.1 times per week (avg ± std dev) from February 2015 to February 2019. Forty-five eyes discontinued monitoring after an average of 65 days (range 13–237 days), due to poor quality tests (62%), and false-positive alerts (16%). Eyes that discontinued device monitoring were older and had poorer visual acuity than eyes that continued monitoring (P < 0.01). Fourteen alerts were generated, of which one represented conversion to exudative AMD. Two additional converted eyes were identified by routine office visit and Amsler grid monitoring. Conclusions: Home monitoring has the potential to improve the detection of exudative AMD. Identifying barriers to device utilization are necessary in the AMD population.

scholarly journals Anti-VEGF therapy of neovascular age-related macular degeneration: from randomized trials to routine clinical practice

2019 ◽  
Vol 12 (2) ◽  
pp. 97-105 ◽  
Author(s):  
R. R. Fayzrakhmanov
Keyword(s):  
Clinical Practice ◽  
Macular Degeneration ◽  
Randomized Clinical Trials ◽  
High Reliability ◽  
Functional Results ◽  
Routine Clinical Practice ◽  
Age Related Macular Degeneration ◽  
Treatment Protocols ◽  
Anti Vegf ◽  
Age Related

Antivasoproliferative therapy is a revolutionary trend in the treatment of neovascular age-related macular degeneration (nAMD), as it is aimed at blocking growth factors of the newly formed vessels. Currently, two anti-VEGF drugs are registered for ophthalmological use, and the search for new molecules is only gaining momentum. Studying new approaches to treatment and developing innovative drugs, modern medicine relies on the data from international randomized clinical trials (RCT). The fact that this direction attracts much scientific interest is explained by high reliability of the data obtained with RCTs. However, when analyzing the effectiveness of anti-VEGF therapy in patients with nAMD in routine clinical practice, many ophthalmologists are confronted with discrepancies between the expected morphological and functional results as predicted by RCTs and those obtained in reality. It is thus important to bear in mind that RCTs simply determine how the dynamics of morphofunctional parameters should look like, whilst the ideal result is only achievable through correct implementation of therapeutic strategy in real clinical practice. The results obtained in the practice of any specialist wholly depend on how carefully the prescribed treatment protocols are followed by doctors and patients, how burdensome the treatment is, as well as on the potential of the medication. This literary review offers a comparative analysis of the results achieved by using anti-VEGF drugs (ranibizumab and aflibercept) obtained in key RCTs and in routine clinical treatment of nAMD patients.

Sign in / Sign up

Export Citation Format

Share Document